Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: David Jones who wrote (1818)	12/4/1998 7:41:00 AM
From: CUBBY	Read Replies (1) \| Respond to of 4140

Sunrise Technologies International, Inc. Successfully Completes $11.8 Million Private Placement Business Wire - December 04, 1998 07:15 FREMONT, Calif.--(BW HealthWire)--Dec. 4, 1998--Sunrise Technologies International, Inc. (Nasdaq/NMS:SNRS) today announced it has successfully completed a private placement of approximately $11.8 million in common stock, priced at $3.50 per share; approximately $6.8 million of which was paid in cash with the remainder paid in notes due on March 15, 1999. The company raised this money exclusively through its own efforts and without a placement agent. The proceeds will be used in part to continue the company's efforts to secure pre-market approval (PMA) from the FDA for treatment of hyperopia (.75 - 2.50 diopters), to plan the launch of the Sunrise Hyperion(TM) LTK System and to continue the company's product development expansion. In addition, the company plans to expand clinical trials for higher levels of hyperopia, presbyopia, and treatment for certain unsuccessful excimer laser procedures for myopia. According to C. Russell Trenary III, president and CEO, "Nearly two-thirds of the money raised came from ophthalmologists who have seen our clinical results or who have used our system in clinical studies to treat hyperopia. We are delighted to receive this continuing support from ophthalmic surgeons." The Sunrise Hyperion(TM) LTK System differs from excimer laser procedures (PRK & LASIK) and traditional incisional surgeries (RK) because no corneal tissue is cut or removed. It is an office based instrument that applies two rings of laser energy, each application in 1.4 seconds to gently heat collagen in the cornea inducing uniform and immediate transition. Founded in 1987, the company produces and markets high technology products revolutionizing treatment methods in eye care. The company develops Holmium laser-based systems which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. These Systems(1) incorporate a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in clinical trials in the United States. Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth, and other risks listed from time to time in the company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the company's judgment, as of the date of this release, and the company disclaims any intent or obligation to update these forward-looking statements. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com. (1) Caution -- Investigational Device: Federal law restricts this device to investigational use in the U.S. CONTACT: Sunrise Technologies International, Inc. Susan Lorigan, 510/623-9001 Ed Coghlan, 510/771-2399 CUBBY

To: David Jones who wrote (1818)	12/4/1998 1:01:00 PM
From: Joe	Read Replies (1) \| Respond to of 4140

David, Looks like someone is buying a lot of stock around noon today. Does this mean the PMA will be filed today or next week? Since it would not be a smart move to issue a press release Friday afternoon, this may mean the release will be next week. I think Sylvester may be the winner. Looks like the placement was over-subscribed. I am happy that I was able to participate, even though I only got half of what I originally wanted. Since I lost the PMA pool, I consoled myself by getting a bunch more SNRS. Upward and onward! Joe